Why Jyong Biotech Ltd.’s (MENS) Stock Is Up 5.85%
As of Thursday, July 02, Jyong Biotech Ltd.’s MENS share price has surged by 5.85%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Commentary & Analysis
Why Jyong Biotech Ltd.’s (MENS) Stock Is Up 10.73%
As of Thursday, July 02, Jyong Biotech Ltd.’s MENS share price has surged by 10.73%, which has investors questioning if this is right time to sell.Tudor Pop
Why Jyong Biotech Ltd.’s (MENS) Stock Is Down 6.75%
As of Tuesday, June 30, Jyong Biotech Ltd.’s MENS share price has dipped by 6.75%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Jyong Biotech Ltd.’s (MENS) Stock Is Up 5.85%
As of Monday, June 29, Jyong Biotech Ltd.’s MENS share price has surged by 5.85%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Jyong Biotech Ltd.’s (MENS) Stock Is Up 10.64%
As of Monday, June 29, Jyong Biotech Ltd.’s MENS share price has surged by 10.64%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | MENS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $160.3 | $261.1 | 25% |
|
| Shares Out (Mil) | 74.3 | 54.3 | 56% |
|
| Institutional Ownership | 1.1% | 92.9% | 2% |
|
| Float (Mil) | 26.9 | 41.5 | 34% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 60 | 677 | 29% |
|
| Price Change (52-week) |
(96.5%) | 51.8% | 2% |
|
| Growth | MENS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (19.9%) | (10.1%) | 20% |
|
| EPS (5yr) | (18.8%) | 15.8% | 14 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (32.2%) | (15.6%) | 17% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MENS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($5) | ($43) | 34% |
|
| EPS (TTM) | ($0.064) | ($1.600) | 37% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($32) | 27% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $10 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | $177 | $174 | 25% |
|
| Valuation | MENS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.52 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MENS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (34.3%) | (47.5%) | 15% |
|
| ROE | 15.6% | (54.9%) | 72% |
|
| Liabilities to Assets | 219.9% | 29.4% | 99% |
|
| F-Score | 3 | 3 | 18% |
|
Jyong Biotech Ltd. did not pass any screens on 9/24/2026.
